You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨天大藥業月內股價累漲119% 開足馬力生產布洛芬等急需藥品
格隆匯 12-20 10:59
格隆匯12月20日丨天大藥業漲超7%,報0.37港元,本月累計漲幅達119%,高見0.385港元創逾五年新高,總市值8億港元。天大藥業昨日公吿,配合國家新十條優化防疫政策要求,公司位於珠海金灣區生物醫藥產業園的研發及製藥基地生產線正全力生產布洛芬等市場急需藥品,全力保障市場供應。公司的託恩布洛芬混懸液/混懸滴劑是非類固醇類的兒童退熱止痛藥,其中,託恩布洛芬混懸液的市場份額位列國內前三。實施優化防疫政策將進一步帶動該產品的銷售。同時,公司去年收購的專治兒童感冒咳嗽的中成藥小兒清熱止咳顆粒的銷售也大幅上升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account